Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/41545
metadata.artigo.dc.title: Pirfenidone: a novel hypothetical treatment for COVID-19
metadata.artigo.dc.creator: Seifirad, Soroush
metadata.artigo.dc.subject: COVID-19
Pirfenidone
Cytokine storm
Oxidative stress
Inflammation
Angiotensin-converting enzyme
Acute Respiratory Distress Syndrome (ARDS)
metadata.artigo.dc.publisher: Elsevier
metadata.artigo.dc.date.issued: Nov-2020
metadata.artigo.dc.identifier.citation: SEIFIRAD, S. Pirfenidone: a novel hypothetical treatment for COVID-19. Medical Hypotheses, [S.l.], v. 144, Nov. 2020.
metadata.artigo.dc.description.abstract: Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibrotic agent with trivial adverse effects. Pirfenidone is approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF) for patients with mild to moderate disease. Pirfenidone could inhibit apoptosis, downregulate ACE receptors expression, decrease inflammation by several mechanisms and ameliorate oxidative stress and hence protect pneumocytes and other cells from COVID-19 invasion and cytokine storm simultaneously. Based on the pirfenidone mechanism of action and the known pathophysiology of COVID-19, I believe that pirfenidone has the potential for the treatment of COVID-19 patients.
metadata.artigo.dc.identifier.uri: http://www.sciencedirect.com/science/article/pii/S0306987720308380
http://repositorio.ufla.br/jspui/handle/1/41545
metadata.artigo.dc.language: en_US
Appears in Collections:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.